Golden Helix's VarSeq Software to Incorporate MedGenome's OncoMD

Bozeman, MT (May 27, 2015) — Today, Golden Helix Inc. announced the integration of MedGenome's OncoMD into their VarSeq software. The integration will provide VarSeq users with the option to access over 2 million annotated cancer variants.

OncoMD is a comprehensive knowledge base of cancer-specific genetic alterations captured from peer-reviewed scientific publications by a team of biomedical curators. After filtering variants of interest using VarSeq, customers can quickly prioritize actionable variants using OncoMD and make clinical decisions based on sensitivity of variants to approved drugs and enrollment to open clinical trials.

"This is an exciting partnership with Golden Helix to be able to deliver a robust medical informatics solution that enables precision medicine in the global clinical market," said Sam Santhosh, CEO of MedGenome.

"Providing VarSeq users with access to OncoMD, allows clinicians to better tailor diagnostic and therapeutic strategies to individual patients", said Andreas Scherer, President and CEO of Golden Helix. "Having key insights to cancer hotspots and known drug sensitivities, essentially moves precision medicine forward."

VarSeq software streamlines the process of annotating and filtering variants obtained from NGS pipelines, allowing both research scientists and clinicians to find variants of interest in a very efficient and straightforward manner. VarSeq simplifies the user interface and provides a scalable architecture featuring repeatable workflows, note taking, reporting, and filter parameter prototyping.

About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 16 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from micro-arrays and DNA sequencing. With our solutions, hundreds of the world's top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications.

About MedGenome
MedGenome Inc. is a genomics-based diagnostics and research company delivering human health care by decoding the genetic information contained in individuals' genomes. MedGenome's mission is to improve global well-being by developing deep insights into diseases at the genetic and molecular level. Through its work with thousands of doctors, hospitals and patients across India, MedGenome leverages the power of big data, next-generation DNA sequencing techniques and sophisticated clinical and analytics capabilities to drive research, disease risk assessment, treatment and management of patient outcome. Its proprietary OncoMD Cancer Analytics Platform offers insight into more than 2 million cancer-related mutations to identify druggable variants in a patient's tumor and couple it to recommended therapies. The company is backed by a team of industry veterans with deep experience in genomics and big data technologies. For more information, visit www.medgenome.com.